이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Gelesis Holdings 관리

관리 기준 확인 0/4

Gelesis Holdings' CEO는 Yishai Zohar, Jan2022 에 임명되었습니다 의 임기는 1.75 년입니다. 총 연간 보상은 $ 5.38M, 7.3% 로 구성됩니다. 7.3% 급여 및 92.7% 보너스(회사 주식 및 옵션 포함). 는 $ 5.40K 가치에 해당하는 회사 주식의 0.63% 직접 소유합니다. 5.40K. 경영진과 이사회의 평균 재임 기간은 각각 1.8 년과 1.8 년입니다.

주요 정보

Yishai Zohar

최고 경영자

US$5.4m

총 보상

CEO 급여 비율	7.3%
CEO 임기	1.8yrs
CEO 소유권	0.6%
경영진 평균 재임 기간	1.8yrs
이사회 평균 재임 기간	1.8yrs

최근 관리 업데이트

Recent updates

Gelesis Holdings: Advancing Biomimetic Superabsorbent Hydrogels For GI-Related Diseases

Apr 19

CEO 보상 분석

Yishai Zohar 의 보수는 Gelesis Holdings 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2023	n/a	n/a	-US$52m
Mar 31 2023	n/a	n/a	-US$57m
Dec 31 2022	US$5m	US$395k	-US$95m
Sep 30 2022	n/a	n/a	-US$45m
Jun 30 2022	n/a	n/a	-US$85m
Mar 31 2022	n/a	n/a	-US$179m
Dec 31 2021	US$4m	US$412k	-US$188m
Sep 30 2021	n/a	n/a	-US$232m
Jun 30 2021	n/a	n/a	-US$195m
Mar 31 2021	n/a	n/a	-US$79m
Dec 31 2020	US$3m	US$400k	-US$38m

보상 대 시장: Yishai 의 총 보상 ($USD 5.38M )은 US 시장( $USD 683.56K ).

보상과 수익: 회사가 수익성이 없는 동안 Yishai 의 보상이 증가했습니다.

CEO

Yishai Zohar (60 yo)

1.8yrs

테뉴어

US$5,383,631

보상

Mr. Yishai Zohar has been Chief Executive Officer, President and Director at Gelesis Holdings, Inc. since January 2022 & serves as its Chief Compliance Officer, Corporate Secretary, Treasurer, Interim Prin...

리더십 팀

이름	위치	테뉴어	보상	소유권
Yishai Zohar	Founder	1.8yrs	US$5.38m	0.63% $ 5.4k
David Pass	COO & Chief Commercial Officer	1.8yrs	US$2.97m	0% $ 0
Alessandro Sannino	Co-Inventor & Lead Project Scientist	no data	데이터 없음	0.19% $ 1.6k
Joy Bauer	Chief Nutrition Officer of Plenity	2.8yrs	데이터 없음	데이터 없음

1.8yrs

평균 재임 기간

54yo

평균 연령

경험이 풍부한 관리: GLSH 의 관리팀은 경험 (평균 재직 기간 1.8 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Yishai Zohar	Founder	1.8yrs	US$5.38m	0.63% $ 5.4k
Bennett Shapiro	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Louis Aronne	Member of Scientific Advisory Board	8.6yrs	데이터 없음	데이터 없음
Alison Bauerlein	Independent Director	1.8yrs	US$202.65k	0% $ 0
Ken Fujioka	Member of Scientific Advisory Board	8.6yrs	데이터 없음	데이터 없음
Caroline Apovian	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Hassan Heshmati	Member of Scientific Advisory Board	3.8yrs	US$533.00k	데이터 없음
James Hill	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Allan Geliebter	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Lee Kaplan	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Clayton Christopher	Independent Director	1.8yrs	US$190.50k	0.63% $ 5.4k
Jane Wildman	Independent Director	1.8yrs	US$197.20k	0% $ 0

1.8yrs

평균 재임 기간

61yo

평균 연령

경험이 풍부한 이사회: GLSH 의 이사회는 경험(평균 재직 기간 1.8 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Gelesis Holdings 관리

관리 기준 확인 0/4

주요 정보

최근 관리 업데이트

Gelesis Holdings, Inc. Appoints Mr. Yishai Zohar as Chief Compliance Officer, Corporate Secretary, Treasurer, Principal Accounting Officer

Elliot Maltz, Treasurer, Chief Compliance Officer and Corporate Secretary (And Principal Financial and Accounting Officer) of Gelesis Holdings, Inc. Resigns from All Positions, Effective August 15, 2023

David Abraham Ceases to Serve as General Counsel, Chief Compliance Officer and Corporate Secretary of Gelesis Holdings, Inc

Director recently bought US$100k worth of stock

No independent directors

Recent updates

Motion for Joint Administration Approved for Gelesis Holdings, Inc.

Gelesis Holdings, Inc. Filed for Bankruptcy

Gelesis Holdings, Inc. Appoints Mr. Yishai Zohar as Chief Compliance Officer, Corporate Secretary, Treasurer, Principal Accounting Officer

Elliot Maltz, Treasurer, Chief Compliance Officer and Corporate Secretary (And Principal Financial and Accounting Officer) of Gelesis Holdings, Inc. Resigns from All Positions, Effective August 15, 2023

Full year 2022 earnings released: US$1.35 loss per share (vs US$32.89 loss in FY 2021)

KLP Enterprises Engages in Discussions with Gelesis Holdings

Gelesis Holdings Receives a Notification Letter from the New York Stock Exchange

Gelesis Holdings Receives Notice of NYSE Market Capitalization Listing Rule Non-Compliance

Third quarter 2022 earnings released: US$0.20 loss per share (vs US$9.61 loss in 3Q 2021)

Gelesis Holdings, Inc. Reiterates Earnings Guidance for the Full Year Fiscal Year 2022

Gelesis Holdings GAAP EPS of -$0.20, revenue of $6.65M

Gelesis Holdings, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Gelesis Holdings Receives Notice of NYSE Trading Share Price Listing Rule Non-Compliance

Gelesis receives NYSE notice of non-compliance

Gelesis Holdings, Inc. to Present Data from the Light Up Study with Gelesis' Oral Hydrogel Treatment Gs200 at Obesity Week

David Abraham Ceases to Serve as General Counsel, Chief Compliance Officer and Corporate Secretary of Gelesis Holdings, Inc

Gelesis Holdings Inc. Presents Clinical Data from the Light-Up Study At the International Congress of Endocrinology

Second quarter 2022 earnings released

Gelesis Holdings, Inc. Provides Revenue Guidance for the Full Year 2022

Gelesis Holdings GAAP EPS of -$0.17, revenue of $8.97M; narrows FY22 guidance

Gelesis Holdings, Inc. to Report Q2, 2022 Results on Aug 15, 2022

Microbiota Transplantation Demonstrates How Gut Bacteria Contributes to Weight Loss and Beneficial Metabolic Effects with Gelesis’ Proprietary Hydrogel

Gelesis Holdings, Inc. Provides Revenue Guidance for the Year 2022

Gelesis Holdings, Inc. to Report Q1, 2022 Results on May 12, 2022

Gelesis Announces Clinical Data Demonstrating Weight Loss with GS200 in Adults with Prediabetes and Type 2 Diabetes Presented at the European Congress on Obesity 2022

Gelesis Holdings: Advancing Biomimetic Superabsorbent Hydrogels For GI-Related Diseases

Gelesis Holdings, Inc. announced delayed annual 10-K filing

Gelesis Holdings, Inc. Provides Revenue Guidance for the Year 2022

Director recently bought US$100k worth of stock

No independent directors

Gelesis, Inc. completed the acquisition of Capstar Special Purpose Acquisition Corp. (NYSE:CPSR) from a group of shareholders in a reverse merger transaction.

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령